Formula I Compounds Inhibiting Kinase Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with abnormal kinase activity, such as those involving Abl, Bcr-Abl, and other kinases, are limited in effectiveness due to resistance mutations and the need for targeted inhibitors that can address various kinase-related disorders.
Innovation Solution
Development of novel compounds of Formula I, which inhibit specific protein kinases by modulating their activity, including Abl, Bcr-Abl, and other kinases, to treat kinase-associated diseases by administering a therapeutically effective amount of these compounds to prevent or inhibit the pathology and symptomology of these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for kinase-associated diseases are used, then treatment effectiveness is limited, but resistance mutations develop
Solution Approach 1:
The compound of Formula I is designed to inhibit multiple kinase targets simultaneously, including Abl, Bcr-Abl, and various mutant forms (such as T315I mutation). This multi-target inhibition capability allows a single compound to address diverse kinase-related disorders and overcome resistance mutations that develop against single-target therapies, thereby improving treatment reliability while reducing the emergence of resistance.
2Adaptability or versatility
If targeted inhibitors are developed to address various kinase-related disorders, then treatment specificity improves, but the complexity of identifying effective targets increases
Solution Approach 1:
The compound of Formula I serves as a pan-kinase inhibitor that can target multiple kinase families and specific kinase members simultaneously. This universal inhibitory profile simplifies the therapeutic approach by providing a single agent that addresses various kinase-related disorders without requiring complex target identification and drug selection processes for each specific kinase mutation or disorder type.
Data Source
AI summary
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-Abl, Bcr-Abl(T315I), ALK5BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-IR, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.